RTGN and TAG transparent 2023-12-04_15-50-47.png
RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy
22 févr. 2024 06h05 HE | RetinalGeniX Technologies, Inc.
RetinalGeniX Granted A New Patent for an Affordable and Effective Device and Method To Detect Ocular And Systemic Diseases
roche-logo-blue.png
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
01 févr. 2024 01h03 HE | F. Hoffmann-La Roche Ltd
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months...
RetinalGeniX Logo Revised Sept 2023.jpg
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
01 déc. 2023 12h32 HE | RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. ANNOUNCES HIRING OF INTERIM CFO Virender Ahluwalia will serve as Interim Chief Financial Officer
Corza Medical's Ophthalmology Center of Technology and Innovation
Corza Medical Opens State-of-the-Art Ophthalmology Center of Technology and Innovation, Demonstrating Commitment to Global Eye Care Community
30 nov. 2023 08h05 HE | Corza Medical Inc.
Corza Medical opens a new Ophthalmology Center of Technology and Innovation in MO to develop next-gen devices for eye treatments and enhance R&D.
IIA Logo_Segment-Beauty.png
SBLA BEAUTY Eye Lift Wand Recognized With “Eye Treatment Product Of The Year ” Award From Beauty Innovation
15 nov. 2023 08h00 HE | Beauty Innovation Awards
LOS ANGELES, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The 2023 Beauty Innovation Awards today announced that the Eye Lift Wand from SBLA BEAUTY has been selected as “Eye Treatment Product Of The Year” in...
New Logo.png
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma
13 nov. 2023 08h00 HE | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal...
RetinalGeniX Logo Revised Sept 2023.jpg
RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
09 nov. 2023 12h58 HE | RetinalGeniX Technologies, Inc.
RetinalGeniX Announces Therapeutic Solutions Being Developed for Dry Age-Related Macular Degeneration and Alzheimer’s Syndrome.
BES_Mark.jpg
NATIONAL VISION ALERT: Bragar Eagel & Squire, P.C. is Investigating National Vision Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
12 sept. 2023 02h30 HE | Bragar Eagel & Squire
NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against National Vision Holdings,...
Full Logo - OKYO .jpg
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center         
28 juil. 2023 07h01 HE | OKYO Pharma LTD
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCPSecond clinical...
Close Up Logo HD Blue.jpg
DEADLINE ALERT for SHC, ARBK, and EYE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
27 mars 2023 12h05 HE | The Law Offices of Frank R. Cruz
LOS ANGELES, March 27, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...